Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma.

CONCLUSIONS: These new drugs now constitute a standard second-line treatment for metastatic tumours and in the future, at least for pembrolizumab, in the first line. Their adjuvant role after locoregional treatment with curative intent is currently under investigation. PMID: 29395567 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research

Related Links:

Conclusion The classification system for NSCLC proposed by our research group is convenient for pathological diagnosis and valuable in clinical application. 
 DOI: 10.3779/j.issn.1009-3419.2018.07.05
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Authors: Engelberg S, Modrejewski J, Walter JG, Livney YD, Assaraf YG Abstract Lung cancer is the leading cause of cancer mortality worldwide, resulting in 88% deaths of all diagnosed patients. Hence, novel therapeutic modalities are urgently needed. Single-stranded oligonucleotide-based aptamers (APTs) are excellent ligands for tumor cell targeting. However, the molecular mechanisms underlying their internalization into living cells have been poorly studied. Towards the application of APTs for active drug targeting to cancer cells, we herein studied the mechanism underlying S15-APT internalization into human non-s...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS: The relative expression of linc00460 is upregulated in NSCLC tissues. Cells and linc00460 can promote the tumor invasion and migration through affecting EMT. PMID: 29509248 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Conclusion: Volume-based PET metrics correlate with PFS and OS and could be used for risk assessment in stage I–II NSCLC. The different PET metrics assessed in this study showed a high correlation; therefore, it is not surprising that there was no significant difference to predict PFS or OS within this study. Overall, patients with large and metabolically active tumors should be considered high risk and might need further treatment after resection. Because all analysis steps were done with the same data, these results should be validated on new patient data.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
Contributors : M Vaz ; S B Baylin ; H P EaswaranSeries Type : OtherOrganism : Homo sapiensWe define how chronic cigarette smoke-induced time-dependent epigenetic alterations can sensitize human bronchial epithelial cells (HBEC) for transformation by a single oncogene. The smoke-induced, chromatin changes include initial repressive polycomb marking of genes later manifesting abnormal DNA methylation by 10 months. At this time, cells manifest epithelial to mesenchymal changes, anchorage-independent growth and upregulated RAS/MAPK signaling with silencing of hyper-methylated genes normally inhibiting these pathways and which ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Other Homo sapiens Source Type: research
Authors: Zeng XJ, Wu YH, Luo M, Cong PG, Yu H Abstract OBJECTIVE: Pulmonary carcinoma is one common malignant tumor with a high risk of recurrence and metastasis. Non-small cell lung cancer (NSCLC) is the most common subtype. As one tumor biomarker, microRNA (miR) has tissue sensitivity and can facilitate oncogene or inhibit tumor suppressor gene. MiR-218 has abnormal expression and can work as one molecular marker for tumors. However, its expression and function mechanism in lung cancer cells have not been fully illustrated. MATERIALS AND METHODS: In vitro cultured pulmonary adenoma A549 cells and normal bronc...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumors are not applicable.
Source: ScienceDaily Headlines - Category: Science Source Type: news
In conclusion, the existence of EMT-like gene expression in NSMs, may play critical role in tumor progression and be a potential biomarker for prognosis in patients with NSCLC. PMID: 27486775 [PubMed - as supplied by publisher]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Baluchova K, Zahradnikova M, Bakes P, Trubacova S, Novosadova H, Halasova E, Majer I, Hlavcak P Abstract Non-small cell lung cancer (NSCLC) is a histologically and molecularly heterogeneous disease predominating in Slovakia among newly diagnosed oncological disorders and leading in the number of associated deaths. NSCLC diagnostics has advanced especially in molecular typing of epidermal growth factor receptor (EGFR) and subsequent targeted molecular therapy using tyrosine-kinase inhibitor(s) (TKI). The selection of patients for targeted therapy, we describe in this study, is mostly guided through bronchia...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Non-small cell lung cancer (NSCLC) is a prevalent and deadly disease because of high incidence and relapse rates. One hypothesis for the high relapse rate is the existence of cancer stem cells (CSCs), a rare subpopulation of cells within these tumors, that are resistant to therapy and thought to be responsible for local and distal recurrence. CSCs are also able to self-renew and differentiate into multiple cell types forming the mass of new tumors. These differentiated progeny that constitute the bulk of the tumor are more sensitive to radiation and chemotherapeutic agents, express tissue of origin markers, and have an int...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Stem Cell of Origin: Poster Presentations - Proffered Abstracts Source Type: research
More News: Bronchial Tumour | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study